Navigation Links
CareFusion Reports First Half Fiscal 2013 Results
Date:2/7/2013

SAN DIEGO, Feb. 7, 2013 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the three and six months ended Dec. 31, 2012.

"Our consolidated first and second quarter financial results were led by strong performance across the Procedural Solutions segment, where each business is delivering positive gains and executing well," said Kieran T. Gallahue, chairman and CEO. "In Medical Systems, the first half shaped up about as we expected, with Infusion Systems performing slightly ahead of our plans. 

"At the same time, we continued to make progress against our strategic goals, expanding operating margins while investing in innovation, new markets and other priorities that will help us accelerate our growth over the long-term."  

Second Quarter ResultsThe company reported revenue for the second quarter of fiscal 2013 of $909 million, compared to $890 million in the second quarter of fiscal 2012, an increase of 2 percent on a reported and constant currency basis.

Operating income was $171 million, an increase of 20 percent compared to $143 million in the prior year period. Excluding nonrecurring items, adjusted operating income for the second quarter grew 12 percent to $189 million, or 20.8 percent of revenue, driven primarily by gross margin expansion.

Operating expenses totaled $300 million in the second quarter. Excluding amortization of acquired intangibles and nonrecurring items, adjusted operating expenses were $282 million, an increase of 1 percent over the prior year period. During the quarter, the company continued to increase investments in research and development, which were primarily funded by decreases in corporate overhead and selling, general and administrative (SG&A) expenses.

The company reported income from
'/>"/>

SOURCE CareFusion Corp.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
2. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
3. CareFusion Expands Infusion Pump Interoperability
4. CareFusion To Report Fourth Quarter And Fiscal 2012 Results On Aug. 9
5. CareFusion Reports Fourth Quarter and Fiscal 2012 Results
6. CareFusion Recognizes Best Of The Best U.S. Hospitals
7. CareFusion Provides Update On Form 10-K Filing
8. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
9. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
10. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
11. CareFusion Files Fiscal 2012 Form 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... N.J. , June 19, 2013 /PRNewswire-iReach/ ... Pharma, a new specialty pharmaceutical company dedicated ... of innovative injectable and sustained release drug ... unmet medical needs, today announced the acquisition ... Linker Technology®) platform and associated product pipeline. ...
Breaking Medicine Technology:Amerivet Solutions Expands to Manufacture Complex Metal Designs 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
... Dec. 5, 2011   New product launches are continually ... critical for organizations to balance the dueling goals of containing ... executives face is determining how much to invest, and how ... budget for primary care launch is spent before ...
... 5, 2011 Technology is revolutionizing healthcare — making ... lowering the cost of care. AT&T ,s* new ... — is designed to do just that. The 2011 ... awarded to AT&T for its approach to mHealth, recognizing ...
Cached Medicine Technology:Launch Spend Insights: Companies Now Invest More in Launch Year Than in Previous 3 Ramp-Up Years Combined 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 3Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 4
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was ... their third in a series of six workshops where people with ... helped place the mosaic tiles in their permanent location under the ... and Greg Maxwell. , This mural project began in March ... root over three years ago with the goal of promoting ...
(Date:6/19/2013)... Food and Drug Administration (FDA) announced last week the approval ... MemoryShape™. , The FDA approved Sientra/Silimed in March 2012 and ... of the MemoryShape™ implant on June 14, 2013. It ... years old or older and in breast reconstruction of women ... six years of data from 955 women participating in trials. ...
(Date:6/19/2013)... years, the mantra of neurologists treating stroke victims has been ... emergency room quickly to receive a drug that dissolves the ... much brain tissue is saved or lost. , ... timing of giving the intravenous drug known as a ... of ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... cancer is many fold higher in persons over 65 ... on how best to treat these older cancer patients. ... clinical trials, those elderly patients who are eventually included ... elderly patient population is not well represented in clinical ... is now starting a new phase 2 trial in ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Fit Body ... Laing recently held a charity boot camp in order to ... The fitness boot camp franchise hosted the Brent ... 11 a.m. with 75 boot camp participants and collected over ... boot camp marks the second fundraiser held for Orlando local ...
Breaking Medicine News(10 mins):Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2
... Milestones in Quarter, SAN JOSE, Calif., Nov. 13 ... or "the Company") today,announced results for the third quarter ... $365,000 in the prior year period,resulted in a net ... a net,income of $49,000 ($.01 per share) for the ...
... its established Life Sciences North American practice building upon the ... ... PHILADELPHIA, Nov. 13 Business & Decision, (http://www.businessdecision.com ) announced the ... focus on providing,Pharmaceutical, Biotechnology, Medical Device and CRO companies with a,range ...
... a single enzyme, telomerase, is associated with the uncontrollable ... percent of all of human cancers. Since the mid-1990s, ... have eyed the enzyme as an ideal target for ... working at The Wistar Institute have brought this goal ...
... Actress and new mom calls vaccine ,family priority, this season ... a Golden Globe (for Alias ) and the heart ... this flu season is to protect the health of the ... influenza, and more than 100 children die every year from ...
... who undergo LDLT develop liver cirrhosis with ... vascular dilatation and collateral pathways. Thus, various ... occur, and adult recipients often present characteristic ... Kyoto University Hospital, Japan (Hori T, Yagi ...
... suggests that the presence or absence of two proteins may ... , One of the proteins, called ErbB-4, is important for ... the body. The second protein, called Wwox, is a tumor ... and it is missing in many breast cancers. Scientists dont ...
Cached Medicine News:Health News:Human Pheromone Sciences Announces Third Quarter Results 2Health News:Human Pheromone Sciences Announces Third Quarter Results 3Health News:Human Pheromone Sciences Announces Third Quarter Results 4Health News:Business & Decision Brings its eClinical Life Sciences Industry offering to North America 2Health News:Business & Decision Brings its eClinical Life Sciences Industry offering to North America 3Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 3Health News:Jennifer Garner Puts Flu Shot in the Spotlight 2Health News:Jennifer Garner Puts Flu Shot in the Spotlight 3Health News:Jennifer Garner Puts Flu Shot in the Spotlight 4Health News:2 proteins may be survival markers in some breast cancers 2Health News:2 proteins may be survival markers in some breast cancers 3
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... light source is a superior choice for ... surgery, headlamps, and dental curing. This is ... light weight, compact and cost competitve with ... light source utilizes the latest in Cermax ...
... The AtheNA Multi-Lyte Test System* ... designed to simultaneously perform multiple assays ... one well. It offers a simple ... ELISA testing, providing improved clinical sensitivity ...
... VITROS 350 Chemistry System offers easy operation, maintenance, ... primary, STAT, or back-up to the powerful VITROS ... get the job done right the first time. ... Systems are efficient, dependable, and easy-to-use. The VITROS ...
Medicine Products: